Gland Pharma Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 21,598,483 (50%) | — | ₹323,977 Cr |
| NII (HNI) | — | 6,479,546 (15%) | — | ₹97,193 Cr |
| Retail | — | 15,118,939 (35%) | — | ₹226,784 Cr |
| Σ Total | — | 43,196,968 (100%) | — | ₹6,479,545 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 10 | ₹15,000 |
| Retail (Max) | 13 | 130 | ₹195,000 |
| S-HNI (Min) | 14 | 140 | ₹210,000 |
| B-HNI (Min) | 67 | 670 | ₹1,005,000 |
Financial Statements Amount in Crore
| Metric | 30-June-20 | 31-Mar-20 | 31-Mar-19 |
|---|---|---|---|
| Revenue | 916 | 2,772 | 2,130 |
| Profit After Tax | 314 | 773 | 452 |
| Total Assets | 4,691 | 4,086 | 3,524 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1 Funding incremental working capital requirements of our Company – 769.50
- 2 Funding capital expenditure requirements of our Company – 168.00
- 3 General corporate purposes – 286.47
Company Overview
Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. It manufactures a diversified range of high-quality complex injectables. The company offers products like sterile injectables, oncology, and ophthalmics, complex injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, First-to-File products, etc.
The company follows a B2B model to sell its products in more than 60 countries including the US, Canada, Australia, India, Europe, etc. Leading pharma companies i.e. Sagent Pharmaceuticals, Apotex Inc. Athnex Pharmaceutical Division, LLC, Fresenius Kabi USA, LLC, etc. are some of the key customers.
It has 7 robust manufacturing units in India comprising 4 finished formulations facilities, 22 production lines, and 3 APIs.
Company Strengths
- The extensive product portfolio of complex injectables.
- Diversified B2B model with a targeted B2C model in India.
- Strong manufacturing capabilities.
- Robust financial track record.
- Experienced and qualified managerial team.